Articles tagged "Graft survival"

2016 American Transplant Congress
Subnormothermic Machine Perfusion (SNMP) with a Novel Hemoglobin-Based Oxygen Carrier (HBOC) Solution for Ex Vivo Preservation in Vascularized Composite Allotransplantation (VCA).
S. Oksuz, R. Schweizer, M. Minervini, B. Banan, V. Gorantla, P. Fontes.
University of Pittsburgh, Pittsburgh.
Background: Improved preservation techniques could reduce ischemia-reperfusion injuries (IRI) and allow better matching and allocation of VCA grafts across wider distances. A novel SNMP system…
2016 American Transplant Congress
Fluctuation of Renal Function During the First Year Is Associated with Negative Impact on Long-Term Kidney Graft Survival: A Retrospective, Propensity Score-Matched Study.
H. Choi,¹ D. Joo,^2,3 M. Song,⁴ M. Kim,^2,3 Y. Kim,^2,3 B. Kim.^1,3
¹Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea; ²Department of Surgery, Yonsei University College of Medicine, Seoul, Korea; ³The Research Institute for Transplantation, Yonsei University College of Medicine, Seoul, Korea; ⁴Department of Biostatistics Collaboration Unit, Yonsei University College of Medicine, Seoul, Korea.
Background: Post-transplant renal function in the first year has been reported to predict long-term renal graft survival. The present study examined whether the fluctuation of…
2016 American Transplant Congress
The Impact of a Novel Dual Adenosine Triphosphate-Competitive mTOR Inhibitor (TORKinib) on Alloimmunity and Transplant Survival.
D. Fantus,¹ Y. Ono,¹ S. Yokota,¹ C. Komatsu,¹ H. Turnquist,^1,2 A. Thomson.^1,2
¹Surgery, Thomas E Starzl Transplantation Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA; ²Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Background: Rapamycin (RAPA), an immunosuppressive agent, inhibits the mechanistic target of Rapamycin (mTOR), the kinase subunit of two mTOR- containing complexes (mTORC1 and mTORC2). While…
2016 American Transplant Congress
Outcomes of Deceased Donor Kidney Transplantation from Diabetic Donors: Does Presence of Recipient Diabetes Matter?
J. Rogers,¹ A. Farney,¹ G. Orlando,¹ A. Reeves-Daniel,² A. Palanisamy,² H. El-Hennawy,¹ M. Khan,¹ M. Gautreaux,¹ S. Iskandar,³ W. Doares,⁴ S. Kaczmorski,⁴ R. Stratta.¹
¹Surgery, Wake Forest Baptist Medical Center, Winston-Salem, NC; ²Internal Medicine, WFBMC, Winston-Salem, NC; ³Pathology, WFBMC, Winston-Salem, NC; ⁴Pharmacy, WFBMC, Winston-Salem, NC.
Donor history of diabetes mellitus (DM) is a known risk factor for inferior graft survival after deceased donor kidney transplantation (DDKT) and is heavily weighted…
2016 American Transplant Congress
Clinical Outcomes of Kidney Allograft Recipients with Apolipoprotein L1 (APOL1) Risk Alleles from Living Kidney Donors.
C. Dorr,^1,2,3 A. Hart,^1,2,3 D. Schladt,¹ A. Muthusamy,¹ R. Mannon,⁴ W. Oetting,² A. Matas,² P. Jacobson,² A. Israni.^1,2,3
¹Minneapolis Medical Research Foundation, Minneapolis; ²University of Minnesota, Minneapolis; ³Hennepin County Medical Center, Minneapolis; ⁴University of Alabama, Birmingham.
Background:Apolipoprotein L1 (APOL1) alleles G1 and G2 in deceased donors are associated with poor kidney allograft survival. However, the effect of these alleles in living…
2016 American Transplant Congress
Chemokine Receptor CXCR4 Antagonist, a Novel Pathway to Prevent Chronic Allograft Nephropathy.
Y. Xu, Q. Zhang, X. Hu.
Department of Urology, Beijing Chaoyang Hospital, Beijing, China.
BackgroundChronic allograft nephropathy (CAN) remains a major problem for long term graft survival and different pathways participate in its development. CXC chemokine receptor 4 (CXCR4)…
2016 American Transplant Congress
Targeting the Constitutively Active PI3K/Akt/mTOR Signaling Pathway in Epstein-Barr Virus B Cell Lymphomas.
A. Sang, G. Ivison, C. Esquivel, S. Krams, O. Martinez.
Division of Abdominal Transplantation, Stanford School of Medicine, Stanford, CA.
Epstein-Barr virus (EBV) B cell lymphomas in post-transplant lymphoproliferative disorder (PTLD) is a major problem in organ transplantation. Reduction of immunosuppression sometimes result in tumor…
2016 American Transplant Congress
Short UK Dialysis Does Not Significantly Impact on Live Donor Kidney Allograft Survival.
A. Bentall,^1,2 M. Jesky,^1,2 R. Borrows,^1,2 R. Johnson,³ S. Ball.^1,2
¹Department of Nephrology, University Hospitals Birmingham, Birmingham, United Kingdom; ²School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom; ³NHSBT, Bristol, United Kingdom.
Background. The survival advantage of pre-emptive transplantation (Pre-empTx) in live donor kidney transplantation (LDKTx) was reported by Meier-Kreische (Kidney International, 2000). Dialysis practices differ internationally…
2016 American Transplant Congress
Delayed Graft Function (DGF) Does Not Accelerate Progression of Fibrosis During the First Year After Deceased Donor Kidney Transplantation.
R. Heilman, I. Qaqish, M. Smith, H. Khamash, B. Kaplan, K. Reddy.
Mayo Clinic, Phoenix, AZ.
BackgroundOur aim was to study the impact of DGF on the progression of interstitial fibrosis during the first post-transplant year.MethodsWe included all patients who received…
2016 American Transplant Congress
Everolimus Decline Anti-ABO Blood Type Antibody Titer in Desensitization for ABO Incompatible Kidney Transplantation.
Y. Wada, N. Fukuzawa, H. Harada.
Kidney Transplantation Surgery, Sapporo City General Hospital, Sapporo, Hokkaido, Japan.
INTRODUCTION: The immoderate donor shortage and sophisticated desensitization protocols resulted in the explosive increase and great success of the ABO blood type incompatible kidney transplantation…